<DOC>
	<DOCNO>NCT00902161</DOCNO>
	<brief_summary>This study assess effect combine treatment MK0893 plus propranolol versus placebo plus propranolol hypoglycemia .</brief_summary>
	<brief_title>A Single-Dose Crossover Study MK0893 Patients With Type 2 Diabetes ( 0893-019 AM4 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Participant Type 2 Diabetes ( T2DM ) Participant either : Not oral antihyperglycemic medication least 6 week ; single oral antihyperglycemic medication peroxisome proliferatoractivated gamma ( PPARgamma ) agonist ( e.g . Avandia ) ; OR combination two antihyperglycemic medication PPARgamma ) agonists Participant receive insulin least 6 month Participant treat PPARgamma agonist least 12 week Participant nonsmoker least 6 month Female participant nonpregnant highly unlikely conceive due surgical sterilization , postmenopausal status , heterosexually active , willing use 2 birth control method Participant history stroke , seizure , neurological disorder Participant tolerate insulin propranolol Participant history asthma , emphysema chronic bronchitis Participant weight loss program maintenance phase treat weight loss medication within 8 week screen Participant may require treatment drug affect immune system corticosteroid Participant history heart failure coronary artery disease Participant history uncontrolled high blood pressure Participant Human Immunodeficiency ( HIV ) , hepatitis B hepatitis C positive Participant history Type 1 diabetes Participant history hypoglycemia unawareness document blood glucose concentration &lt; 55 mg/dL ( 3.1 mol/L ) without symptom hypoglycemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>